GlassScriptPhysician profile
Justin M Lay
NPI 1093109316
$2,407.03
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $261 · 2021: $231 · 2022: $470 · 2023: $436 · 2024: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $706.18 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $418.46 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $231.41 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $196.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $170.44 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $168.48 | 2019-2024 | |
| Pfizer INC. | $134.49 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $60.29 | 2021-2023 | Qelbree |
| Genentech USA, INC. | $53.87 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $45.39 | 2024 | Daybue |
| Kaleo, INC. | $45.22 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $35.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.25 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $21.77 | 2024 | Flumist Quadrivalent |
| Abbott Laboratories | $20.98 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $15.74 | 2019 | |
| Seqirus USA INC | $15.73 | 2024 | Flucelvax, Fluad |
| Sanofi-Aventis U.S. LLC | $15.50 | 2024 | |
| Glaxosmithkline, LLC. | $12.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.